Drug Profile
Intravenous iron - Shield Therapeutics
Alternative Names: PT-30Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Medical Research Council; Phosphate Therapeutics
- Developer Shield Therapeutics
- Class Antianaemics; Heavy metals; Iron compounds
- Mechanism of Action Iron replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Iron deficiency anaemia
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Iron deficiency anaemia in Switzerland (IV)
- 08 Oct 2018 Preclinical trials in Iron deficiency anaemia in Switzerland (IV) (Shield Therapeutics pipeline, October 2018)